Autoimmune diseases can’t be cured, but most can be managed well enough to reach remission or something close to it. Treatment typically combines medication to calm the immune system, lifestyle changes to reduce inflammation, and regular monitoring to catch flares early. The specific approach depends on which condition you have and how severe it is, but the core strategy is the same: stop the immune system from attacking healthy tissue while preserving enough immune function to fight real threats.
How Autoimmune Treatment Works
In autoimmune disease, your immune system mistakes your own cells for invaders and launches an inflammatory attack. Treatment works by dialing down that overactive response. The goal, increasingly adopted across rheumatology guidelines, is called “treat to target.” Rather than simply reducing symptoms, doctors aim for a specific measurable outcome: remission if possible, or low disease activity if not. This means adjusting medications over time based on how well your inflammation markers and symptoms respond.
For lupus, the 2023 European guidelines emphasize early diagnosis, prompt treatment, and strict medication adherence as the foundation for preventing organ damage and improving long-term quality of life. That principle applies broadly across autoimmune conditions.
Medications That Calm the Immune System
Most autoimmune treatment starts with disease-modifying drugs, commonly called DMARDs. These are the workhorses of autoimmune care, used across rheumatoid arthritis, lupus, psoriatic arthritis, inflammatory bowel disease, multiple sclerosis, scleroderma, and many others. They come in two main categories.
Traditional DMARDs
Traditional DMARDs broadly suppress the entire immune system. They’re usually the first medications prescribed because they’re well understood, widely available, and effective for many people. Your doctor may start with a single traditional DMARD, combine two or more, or pair one with a short course of corticosteroids to get inflammation under control quickly. For lupus specifically, hydroxychloroquine is recommended for virtually all patients as a baseline treatment.
Biologics
Biologics are newer, more precise medications made from proteins that target specific parts of the immune system rather than suppressing it broadly. Some block a protein called TNF that drives inflammation. Others target specific immune-signaling molecules, or go after particular types of immune cells (T-cells or B-cells) that are causing damage. Because they’re more targeted, biologics can be effective when traditional DMARDs aren’t enough, though the precision cuts both ways. A biologic that works brilliantly for one condition can sometimes worsen another. Blocking one inflammatory pathway in the gut, for example, has actually triggered flares in inflammatory bowel disease because that pathway also plays a protective role in intestinal lining integrity.
Biologics are typically added on top of a traditional DMARD rather than replacing it entirely.
JAK Inhibitors
JAK inhibitors are oral medications that target specific enzymes inside immune cells. They’re now approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, atopic dermatitis, alopecia areata, and vitiligo. In head-to-head trials, some JAK inhibitors have matched or outperformed established biologic treatments. In rheumatoid arthritis, for instance, one JAK inhibitor combined with a traditional DMARD proved statistically superior to a widely used biologic in patients who hadn’t responded to first-line treatment. For psoriatic arthritis, results were similarly strong, with one JAK inhibitor outperforming a standard biologic in patients who hadn’t responded well to initial therapy.
Corticosteroids
Corticosteroids reduce inflammation fast, which makes them useful during flares or while waiting for slower-acting DMARDs to kick in. But they come with significant trade-offs over time. Long-term use raises blood sugar (they increase insulin resistance), can push cholesterol and triglyceride levels up dramatically, and weakens bones. Roughly 25% of people on long-term immunosuppression after organ transplant experience a fracture, and corticosteroids are a major contributor to that risk. Current guidelines push to keep corticosteroid doses as low as possible, ideally tapering off entirely when other medications are controlling the disease.
Risks of Long-Term Immune Suppression
Suppressing the immune system controls autoimmune damage, but it also reduces your ability to fight infections. Infection risk is highest in the early months of treatment when doses tend to be highest. As your doctor tapers medications and finds the minimum effective dose, that risk decreases but doesn’t disappear. Metabolic side effects are also common with several classes of immune-suppressing drugs. Up to 60% of people on certain immunosuppressant regimens develop high cholesterol or high triglycerides. Regular blood work to monitor these changes is a standard part of treatment.
This is why the treat-to-target approach matters. The goal isn’t maximum suppression but the least amount of medication needed to keep the disease quiet.
How Doctors Track Your Progress
Treatment success isn’t just about how you feel, though that matters enormously. Doctors use blood tests to measure inflammation objectively. Two common markers are C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), both of which rise when inflammation is active. For specific conditions like lupus, antibody levels in the blood can track disease activity. Newer research is identifying more precise biomarkers, including specific antibody subtypes that can predict how well a particular treatment will work for an individual patient, potentially allowing doctors to choose the right medication faster.
You’ll likely have blood work done regularly, especially when starting or changing medications. The frequency depends on your condition and treatment, but every few months is typical once things stabilize.
Diet and Nutritional Approaches
The autoimmune protocol (AIP) diet eliminates foods thought to trigger inflammation, including grains, dairy, legumes, refined sugars, and nightshade vegetables, then gradually reintroduces them to identify personal triggers. A pilot study in people with rheumatoid arthritis found meaningful results: over eight weeks on the AIP diet, average disease activity scores dropped from 2.73 out of 10 to 0.99. Three participants reached remission from low disease activity, and most reported improvements in fatigue, sleep, and pain.
This was a small study without a control group, so it doesn’t prove the diet works for everyone. But it suggests that dietary changes can meaningfully complement medical treatment for some people. The broader principle, reducing processed food and identifying personal food triggers, is low-risk and worth exploring.
Vitamin D and Omega-3 Supplements
A large randomized controlled trial called VITAL followed over 25,000 people for five years and found that vitamin D supplementation reduced the incidence of autoimmune disease by 22%. When only the last three years of the study were considered (allowing time for the supplement to take effect), that reduction climbed to 39%. Omega-3 fatty acid supplementation showed a 15% reduction that wasn’t statistically significant on its own, but combining both supplements together reduced autoimmune disease incidence by about 30% compared to placebo. These findings suggest that for people at risk of autoimmune disease, or those already managing one, vitamin D and omega-3s may offer a real protective benefit alongside standard treatment.
Exercise as Treatment
Regular moderate-intensity exercise improves fatigue, physical function, and aerobic capacity across multiple autoimmune conditions, including lupus, rheumatoid arthritis, scleroderma, and multiple sclerosis. A combination of aerobic training and strength training is recommended as routine practice for people with rheumatoid arthritis specifically. The target is 150 minutes per week of moderate-to-vigorous physical activity, though roughly 60% of people with autoimmune rheumatic disease don’t currently hit that mark.
The key is starting gradually. Exercise should be comfortable, with rest breaks as needed, and scaled up slowly to avoid triggering a flare. On days when symptoms are active, lighter activity or rest is appropriate. The goal is consistency over intensity. Even modest regular movement reduces the systemic inflammation that drives autoimmune damage.
Experimental Treatments on the Horizon
CAR-T cell therapy, originally developed for blood cancers, is showing remarkable early results in severe autoimmune disease. The treatment reprograms a patient’s own immune cells to seek out and destroy the B-cells producing harmful autoantibodies. In a landmark 2021 case, a 20-year-old woman with severe lupus that hadn’t responded to standard treatments achieved complete remission within three months of a single CAR-T infusion. She was able to stop all immunosuppressive medications, including corticosteroids, and showed no signs of relapse over 18 months. A follow-up study of five lupus patients found all achieved remission within three months, with most harmful autoantibodies dropping to normal levels. The treatment was well tolerated, with only mild fever as the most common side effect.
Early trials have expanded to scleroderma with similarly promising results. CAR-T therapy is not yet widely available for autoimmune disease and remains in the clinical trial phase, but it represents a potential shift from lifelong immune suppression to a one-time treatment that resets the immune system.